Table 2. VIA positivity and (pre)malignancy detection rate.
| VIA+ | CIN I | CIN II | CIN III | Cxca | ||
|---|---|---|---|---|---|---|
| No. screened | Number (%) | Number (detection rate in %) | ||||
| Overall | 22 040 | 989 (4.5) | 287 (1.3) | 147 (0.7) | 107 (0.5) | 40 (0.2) |
| <19 | 151 | 3 (2.0) | 1 (0.7) | 0 (0.0) | 1 (0.7) | 0 (0.0) |
| 20–29 | 4652 | 174 (3.7) | 46 (1.0) | 25 (0.5) | 26 (0.6) | 1 (0.02) |
| 30–39 | 8169 | 412 (5.0) | 129 (1.6) | 63 (0.8) | 40 (0.5) | 8 (0.1) |
| 40–49 | 6006 | 282 (4.7) | 86 (1.4) | 46 (0.8) | 27 (0.4) | 14 (0.2) |
| 50–59 | 2607 | 84 (3.2) | 21 (0.8) | 8 (0.3) | 9 (0.3) | 6 (0.2) |
| >60 | 351 | 22 (6.3) | 1 (0.3) | 4 (1.1) | 3 (0.9) | 10 (2.8) |
| Age unknown | 104 | 12 (11.5) | 3 (2.9) | 1 (1.0) | 1 (1.0) | 1 (1.0) |
VIA-positive patients including suspect for malignancy. CIN III including 2 cases of adenocarcinoma in situ, 1 in the 20–29 and 1 in the 40–49 age group and including 18 cases diagnosed as carcinoma in situ. Cxca; cervical carcinoma, including micro- and macroinvasive squamous cell carcinoma and adenocarcinoma.